可重新定位的GORE EXCLUDER AAA内假体(配备C3输送系统)在主动脉髂动脉瘤适应证内治疗中较原GORE EXCLUDER AAA内假体有效性提高
回顾性分析2004–2017年313例连续患者,比较原GORE EXCLUDER(n=174)与可重新定位C3系统(n=139)治疗肾下主动脉髂动脉瘤的术中主要复合结局。新 device 组主要复合结局发生率更低(3.6% vs 10.9%,OR 0.30,95%CI 0.11–0.84,P=0.016)。Gore Dryseal 鞘组术中输血率更低(1.1% vs 18.9%,OR 0.05,95%CI 0.006–0.35,P<0.001)。
要点
- 新 device 组术中主要复合结局发生率 3.6%,原 device 组 10.9%(OR 0.30,P=0.016)。
- 差异主要由远端错位或移位驱动(2.9% vs 10.3%,P=0.01),多需放置主动脉延长段。
- Gore Dryseal 鞘组术中输血率 1.1%,原 Gore 鞘组 18.9%(OR 0.05,P<0.001)。
核心结论
- 可重新定位的GORE EXCLUDER较原 device 具有重要安全性特征且长期有效性等效,Gore Dryseal 鞘带来额外获益。
研究设计与样本
- 回顾性分析前瞻性收集的信息,连续纳入2004–2011年及2011–2017年接受原GORE EXCLUDER(n=174)或新 device(n=139)治疗肾下主动脉髂动脉瘤或孤立性髂总动脉瘤的313例患者(男303例;中位年龄73岁)。
- 嵌套子研究分析标准 Gore 与 Gore Dryseal 导引鞘对术中输血需求的相对影响。
主要发现
- 主要复合结局(术中主体近端或远端错位或移位)原 device 组 10.9% vs 新 device 组 3.6%(OR 0.30,95%CI 0.11–0.84,P=0.016),多因素 logistic 回归证实。
- 差异完全由远端错位或移位驱动:原 device 组 10.3% vs 新 device 组 2.9%(P=0.01),多需放置主动脉延长段。
- Gore Dryseal 鞘组术中输血率 1.1% vs 原 Gore 鞘组 18.9%(OR 0.05,95%CI 0.006–0.35,P<0.001)。
- 平均随访1.7年(最长13年),11例发生复合事件;单因素 Cox 分析显著预测因素包括女性(P=0.003)、无血脂异常(P=0.023)、主要结局指标(P=0.006)、插管失败(P=0.009),device 类型及其他变量不显著。
- 多因素 Cox 回归独立预测因素:女性(HR 37,P<0.001)、慢性阻塞性肺疾病(HR 3.99,P=0.045)、主要结局指标(HR 8.9,P=0.002)、插管失败(HR 43,P=0.003)。
临床怎么用
- 原文结论认为可重新定位的GORE EXCLUDER较原 device 具有重要安全性特征且长期有效性等效,Gore Dryseal 鞘带来额外获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare two endograft types, the original GORE EXCLUDER AAA endoprosthesis (W. L. Gore & Associates, Flagstaff, Ariz) with the repositionable GORE EXCLUDER featuring the C3 delivery system, which allows repositioning of the proximal part of the graft to achieve accurate placement in relation to the renal arteries, in unselected patients with aortoiliac aneurysms. In a second nested, substudy we investigated the relative effect of the standard Gore and Gore Dryseal introducer sheaths on intraoperative transfusion needs. METHODS: We retrospectively analyzed prospectively collected information. The primary composite outcome measure was the intraoperative misdeployment or migration of the endograft's main body, proximally or distally to the renals (leading to technical failure or requiring either placement of aortic cuff extenders or conversion to open repair). Secondary outcome measures included the composite long-term event of rupture and/or type I/III endoleak. RESULTS: A total of 313 consecutive patients (303 males; median age, 73 years) had either an original GORE EXCLUDER device (n = 174) or the new device (n = 139) placed between 2004 and 2011 and 2011 and 2017, respectively, to treat an infrarenal aortoiliac aneurysm or an isolated common iliac artery aneurysm. The primary composite outcome measure occurred more often in patients who had the original GORE EXCLUDER device placed (10.9% vs 3.6% for the new device; odds ratio, 0.30; 95% confidence interval, 0.11-0.84; P = .016), confirmed by multivariate logistic regression analysis. This difference between the two groups was exclusively driven by distal misdeployment or migration of the endograft (10.3% vs 2.9% for the new device; P = .01), mostly requiring aortic extender placement. Intraoperative blood transfusion rates were lower in patients who had the GORE Dryseal introducer sheath used (1.1% vs 18.9% for the original GORE introducer sheath; OR, 0.05; 95% confidence interval, 0.006-0.35; P < .001). At a mean follow-up of 1.7 years (maximum, 13 years), 11 patients developed the composite event. On univariate Cox analysis, significant predictors included female gender (P = .003), absence of dyslipidemia (P = .023), the primary outcome measure (P = .006), and failure to cannulate (P = .009), but not device type or other variables. On multivariate Cox regression, female gender (hazard ratio, 37; P < .001), chronic obstructive pulmonary disease (hazard ratio, 3.99; P = .045), the primary outcome measure of the study (hazard ratio, 8.9; P = .002), and failure to cannulate (hazard ratio, 43; P = .003) were all independent predictors. CONCLUSIONS: Our study has demonstrated that the repositionable GORE EXCLUDER has important safety characteristics compared with the original device and equivalent long-term effectiveness. Additional benefit was obtained with the use of the Gore Dryseal introducer sheath.
引用
- Tsolakis IA, Kakkos SK, Papageorgopoulou CP, et al. Improved effectiveness of the repositionable GORE EXCLUDER AAA endoprosthesis featuring the C3 delivery system compared with the original GORE EXCLUDER AAA endoprosthesis for within the instructions for use treatment of aortoiliac aneurysms. J Vasc Surg. 2018. PMID: 30108007. doi:10.1016/j.jvs.2018.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。